| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
5
5
4
1
5
|
|
Zacks Investment Research
2
(Buy)
|
|
Standard & Poor's
3 / 5 Stars
|
|
TheStreet.com
B+
(Buy)
|
#11 in Health
U.S. News evaluated 38 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
Performance
The fund has returned 39.38 percent over the past year, 24.32 percent over the past three years, 18.83 percent over the past five years, and 12.80 percent over the past decade.
| Trailing Returns | Updated 04.30.2013 |
|---|---|
| Year to date | 26.0% |
| 1 Year | 39.4% |
| 3 Years (Annualized) | 24.3% |
| 5 Years (Annualized) | 18.8% |
| 10 Years (Annualized) | 12.8% |
Summary
The investment seeks capital appreciation. The fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It will invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.
Fees
Fees are Low compared to funds in the same category.
Rydex Series Trust Biotechnology Fund has an expense ratio of 1.61 percent.
Risk
Risk is Above Average compared to funds in the same category according to Morningstar.
